- $40.35m
- $28.80m
- $69.30m
- 38
- 53
- 15
- 27
Annual cashflow statement for TELA Bio, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -28.8 | -33.3 | -44.3 | -46.7 | -37.8 |
| Depreciation | |||||
| Amortisation | |||||
| Deferred Taxes | |||||
| Non-Cash Items | 3.97 | 5.77 | 7.74 | 7.03 | 0.346 |
| Unusual Items | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | -0.156 | -3.46 | -5.38 | -2.03 | -4.97 |
| Change in Accounts Receivable | |||||
| Change in Inventories | |||||
| Change in Prepaid Expenses | |||||
| Change in Accounts Payable | |||||
| Change in Accrued Expenses | |||||
| Change in Other Liabilities | |||||
| Net Change in Other Assets & Liabilities | |||||
| Cash from Operating Activities | -24.5 | -30.4 | -40.7 | -40.9 | -41.6 |
| Capital Expenditures | -0.167 | -0.627 | -1.87 | -0.611 | -0.989 |
| Purchase of Fixed Assets | |||||
| Purchase / Acquisition of Intangibles | |||||
| Other Investing Cash Flow Items | 9.29 | 0 | 0 | 0.012 | 5.44 |
| Sale of Fixed Assets | |||||
| Sale/Maturity of Investment | |||||
| Cash from Investing Activities | 9.12 | -0.627 | -1.87 | -0.599 | 4.45 |
| Financing Cash Flow Items | -0.522 | 0 | -3.62 | -0.289 | -0.369 |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 44.4 | 0.585 | 40.9 | 46.3 | 43.1 |
| Foreign Exchange Effects | |||||
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | 29.1 | -30.5 | -1.91 | 4.97 | 5.94 |